SEMAGLUTIDE 10mg
- ≥99% purity by HPLC
- Janoshik COA with every lot
- Lot-traceable from synthesis
- EU-synthesised
Specifications
Third Party Lab Tested
Every lot is independently HPLC-tested by Janoshik Analytical, Europe's reference laboratory for peptide purity assessment. The COA shipped with your order is theirs, not ours.
Storage & Handling
Lyophilized peptides should be stored below 16°C, protected from light and moisture, for up to 24 months. Once reconstituted, refrigerate and use within 30 days for protocol consistency.
Reconstitution
Reconstitute with bacteriostatic water using the volumes below. Add solvent slowly along the inside wall of the vial. Swirl gently, never shake, until fully dissolved.
Lab-handling protocol BAC Water · 0.9% benzyl alcohol The reconstitution solvent referenced above. Add to order →Single-pathway GLP-1 research.
Semaglutide is a 31-amino-acid GLP-1 receptor agonist modified for albumin binding and extended activity in experimental models. Its single-receptor profile makes it a defined comparator for research involving dual-pathway Tirzepatide and triple-pathway Retatrutide. This 10 MG Semaglutide peptide is supplied as a lyophilized vial in the NZM-Labs peptide catalogue.
Each production lot receives independent HPLC purity analysis and mass-spectrometry identity testing, with lot-specific documentation available through the Science section. For laboratory research only.
| Compound | Semaglutide |
|---|---|
| Sequence length | 31 amino acids |
| Molecular mass | 4113.6 Da |
| Modeled half-life | ~7 days (modeled) |
| Mechanism / research class | GLP-1R agonist |
| Example laboratory preparation | 10 MG vial with 2 mL bacteriostatic water (0.9% benzyl alcohol) |
| Calculated concentration | 5 mg per 1.0 mL |
| Supply format | Semaglutide · 10 MG lyophilized research vial |
| Storage, lyophilized | store below 16°C for up to 24 months |
| Storage, reconstituted | refrigerate and use within 30 days |
Synthesised.
Verified.
Documented.
Backed by research.
Measured in results.
Each tag opens the cited literature behind that effect. References are linked to PubMed.
Semaglutide is the deepest-cited single-pathway GLP-1 receptor agonist in metabolic research. The reference STEP-1 trial reported −14.9% mean body-weight reduction at 68 weeks in the published reference study arm - the baseline for any GLP-1 / GIP / GCG comparison.
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. NEJM. 2021;384(11):989-1002. PubMed ↗
GLP-1 receptor agonism amplifies glucose-dependent insulin secretion. Across the SUSTAIN trial program, Semaglutide produced A1C reductions of 1.4–1.8% in T2D research populations.
- Sorli C et al. Efficacy and safety of once-weekly semaglutide. Lancet Diabetes Endocrinol. 2017;5(4):251-260. PubMed ↗
The SELECT cardiovascular outcomes trial reported a 26% relative reduction in major adverse cardiovascular events (MACE) on Semaglutide vs placebo in T2D populations with established CVD over 39.8 months.
- Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. NEJM. 2023;389(24):2221-2232. PubMed ↗
Questions?
We have answers.
No reviews yet
Write a review
Share your experience with SEMAGLUTIDE 10mg. Reviews are published after a manual check.